STEPHY.T.P et al. 2017. Comparison of quality of life (QOL) for patients with breast Cancer receiving adjuvant tac (docetaxel, doxorubicin, Cyclophosphamide) and fac (5-fluorouracil, doxorubicin, Cyclophosphamide) therapy. International Journal of Pharma and Bio Sciences. 8, 3 (Sep. 2017), 373–382. DOI:https://doi.org/10.22376/ijpbs.2017.8.3.p373-382.